Shubhanshu Shukla, first Indian in space in 41 years, will blast off in a Musk rocket
In Mr Shukla's hometown of Lucknow, posters wishing him luck dot the city. PHOTO: AFP
Shubhanshu Shukla, first Indian in space in 41 years, will blast off in a Musk rocket
NEW DELHI - More than four decades after the first person from India went to space, the nation is finally about to have a sequel.
Mr Shubhanshu Shukla, an Indian Air Force test pilot, will be one of four astronauts aboard a SpaceX Dragon spacecraft on a flight scheduled to launch on June 11 from the Kennedy Space Centre in Florida.
The mission will be operated by Texas-based startup Axiom Space and will have a multinational crew that will also include Commander Peggy Whitson of the US, Mission Specialist Sławosz Uznański-Wiśniewski of Poland and Mission Specialist Tibor Kapu of Hungary. They will spend as many as 14 days at the International Space Station.
No Indian has been in orbit since Mr Rakesh Sharma, who flew on a Soviet rocket in 1984, and the return to space has created a flurry of excitement in the South Asian nation.
In Mr Shukla's hometown of Lucknow, about 560km east of New Delhi, posters wishing him luck dot the city and passersby stop and click selfies with his cut-outs.
Local media reported how Israeli astronaut Eytan Stibbe, part of a 2022 Axiom mission to the ISS, met Mr Shukla's family in May and addressed their anxieties.
Mr Shukla's flight will be the opening act for Indian Prime Minister Narendra Modi's space ambitions in the coming years as his government tries to narrow the gap with nations such as China, which operates its own space station and has plans for a crewed lunar mission by 2030.
India landed a robotic spacecraft near the moon's south pole in 2023, and the state-run Indian Space Research Organisation aims to launch Mr Shukla and three other Indian astronauts on one of the agency's own rockets in 2027 for India's first crewed space mission.
Other plans include Nisar, a joint US-India Earth-observation mission that Nasa and ISRO are targeting to launch this month in June from the Indian agency's space centre in Sriharikota, near Chennai.
ISRO also wants to create an Indian space station by 2035 and put an Indian astronaut on the moon by 2040.
India's decision to deepen its space exploration efforts has won support from the global space community.
In May, the European Space Agency signed a statement of intent to cooperate with ISRO on space exploration and a delegation from Japan's space agency went to ISRO headquarters to discuss plans for a lunar mission.
'It is India's time now,' said Mr Sudheer Kumar N, former director at ISRO's Capacity Building Program Office and an adviser on space projects. India can benefit from the country's ability to complete missions at a competitive cost and Mr Modi's policy to encourage private-sector investment in the industry, he said.
India's return to space was briefly threatened last week by the crossfire between the US President Donald Trump and billionaire Elon Musk after Mr Musk said in a social media post that he was going to decommission SpaceX's Dragon spacecraft that's supposed to carry Shukla and others to the ISS. This was after Mr Trump spoke of cancelling Musk's government subsidies and contracts.
Hours later, Mr Musk clarified Dragon will not be decommissioned.
Mr Shukla's mission could provide important input for the Gaganyaan program, ISRO's human spaceflight initiative.
For instance, as part of a joint project between ISRO and Nasa, he will take fenugreek seeds and mung beans to germinate in space. Investigating space's impact on the plants could help future missions produce food, according to Nasa.
'The feedback, learnings from this trip will be used in fine-tuning and planning the Gaganyaan mission,' said Mr Kumar. BLOOMBERG
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
12 hours ago
- Straits Times
Why China biotech is getting a DeepSeek moment too
Workers working at a Sinovac Covid-19 vaccine production line in Beijing in 2021. So far, the biotech industry is relatively insulated from Mr Trump's tariffs. PHOTO: XINHUA From artificial intelligence to military defence, China has offered a few DeepSeek moments in 2025 , showcasing that the country is more than just the world's biggest factory, and that it also can compete with the US on the technology front. Now biotech is having its own. In late May, Pfizer agreed to pay a record US$1.25 billion (S$1.6 billion) upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late in 2024 for US$800 million. Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
19 hours ago
- Business Times
Why China biotech is getting a DeepSeek moment, too
FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the country is more than just the world's biggest factory, and that it also can compete with the United States on the technology front. Now biotech is having its own. In late May, Pfizer agreed to pay a record US$1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol-Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late last year for US$800 million. Increasingly, big pharmaceutical companies are seeing Chinese biotech as the disruptors. These two deals will allow Pfizer and Bristol-Myers Squib to go after Merck & Co's Keytruda, the world's top-selling medicine. 3SBio's drug works in the same way as a therapy from China's Akeso, which outperformed Keytruda in one trial. US-based Summit Therapeutics licensed Akeso's assets for US$500 million upfront in late 2022. Excitement These billion-dollar deals got bankers and investors excited. The Hang Seng Biotech Index is up about 60 per cent this year. By comparison, the S&P biotech index is down 6.5 per cent. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up There are good reasons to believe this rapid pace of dealmaking and enthusiasm for China biotech will last, with US President Donald Trump's economic policies serving as a major catalyst. Trump's threats to slash US prescription drug costs by '59 per cent, PLUS', as well as Medicaid and Medicare cuts in his big, beautiful tax and spending bill, will inevitably dent Big Pharma's bottom line. To cut in-house R&D expenses, these multinationals might have to come to China, where early-stage human tests are much cheaper and easier to run, despite comparable safety protocols. So far, the biotech industry is relatively insulated from Trump's tariffs, providing a meaningful safe haven for global investors. Rare earths materials and Boeing plane deliveries might be used as negotiation tools, but Beijing is making an exception for public health. It continues to welcome American-made medical supplies, including Pfizer's lung cancer drug Lorbrena and Merck's Gardasil, a HPV vaccine that protects against cervical cancer. Being in Beijing's good books allows Big Pharma to seal licensing deals with local partners. In addition, global drug companies and venture capital funds might want to take equity stakes too, just like Pfizer did last month. With a dip in biotech funding, especially in China, startups are unable to advance drugs on their own, and therefore demand large upfront licensing payments. This gives Western companies leverage to negotiate good deals. What is innovation without human talent? China's 'engineer dividend' is likely to pay off big time in the next few years, propelled by a hostile White House that vows to 'aggressively revoke' visas of Chinese studying in 'critical fields'. Already, the number of Chinese students in the US has dropped 22 per cent from its pre-pandemic peak, with many pointing to anti-Asian sentiment during Covid as a major drawback. Going forward, more could be forgoing US university degrees and working for promising startups at home instead. Between 2000 and 2020, the number of engineers in China ballooned from 5.2 million to 17.7 million, according to the State Council. The discipline and medicine are among the most popular fields for graduate studies. Those under the age of 30 account for 44 per cent of the total engineering pool, versus 20 per cent in the US, according to data compiled by Kaiyuan Securities. As a result, compensation for researchers is only about one-eighth that in the US. In other words, Chinese engineers are young, cheap and abundant. Tailwinds So what we've got are a lot of tailwinds: A group of strategic buyers eager to cut expenses and outsource research, a relatively benign local authority, and competitive talents. China's biotech industry is starting to dazzle. BLOOMBERG
Business Times
a day ago
- Business Times
Musk is the US$350 billion Rocket Man who fell to Earth
THE popcorn emoji is out in force as the world's richest person feuds with its most powerful leader. Even Thierry Breton, the European regulator who was a frequent target of Elon Musk's ire, is at it. Still, as entertaining as the billionaire's spat with Donald Trump may be, it also carries costly lessons for a US$630 billion space economy dominated by Musk's Space Exploration Technologies, or SpaceX – such is the danger of co-dependence between de facto monopolies and increasingly protectionist states. This danger wasn't high on the agenda at the peak of Trump's 'bromance' with Musk, when the then-president-elect described SpaceX's reusable rocket revolution in the way a Renaissance monarch might have praised a successful colonial expedition – with a mix of national pride, geopolitical influence and financial potential: 'I called Elon. I said, 'Elon, was that (landing manoeuvre) you?' He said, 'Yes, it was.' I said, '...Can Russia do it?' 'No.' 'Can China do it?' 'No.' 'Can the United States do it, other than you?' 'No, nobody can do that.' 'That's why I love you, Elon.'' Since then, the love has turned to stardust as the contradictions inherent in Musk's US$350 billion space empire spill over. The hypocrisy of a billionaire pitching himself as 'dark Maga' – 'Make America Great Again' – and taking a chainsaw to government spending while SpaceX (and Tesla) benefits from US$22 billion worth of government contracts is exacerbating the clash of egos, with Trump threatening to withdraw taxpayer support. Meanwhile, Musk's casual threat – quickly withdrawn – to halt the Dragon capsule upon which the National Aeronautics and Space Administration (Nasa) relies to ferry astronauts echoed the geopolitical blackmail exerted on the battlefield in Ukraine, where the billionaire has in the past halted attacks against Russia via SpaceX unit Starlink. These are high-stakes threats with huge societal costs. We are no longer in the realm of enterprising conquistadors but conflicted taxpayer-backed trade empires. Even if Musk deserves credit for his part in SpaceX's domination in both rocket launches and satellite communications, with 80 per cent market share in the former and more than 8,000 Starlink satellites in orbit, the feud's weaponisation of space suggests innovation has taken a backseat to favouritism. SpaceX's successes this year have not been on the launchpad but rather inside the corridors of power, where its market share looks like a lever for rent extraction instead of exploration. Rule changes to high-speed Internet subsidies have opened the door to Starlink awards, as has the prospect of a defence 'Golden Dome'. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Trump's tariff bullying of other countries has been reportedly accompanied by a push for regulatory approvals for Starlink. And putting a Musk ally atop Nasa appears to have been a last straw for the Maga movement. While Nasa and the Pentagon remain heavily reliant on SpaceX, the silver lining to all this is that Musk's competitors must get the message and step up their game. US commercial space companies including Jeff Bezos' Blue Origin have been contacted by government officials about rocket readiness, according to the Washington Post (owned by Bezos). Over in the European Union, which is desperately trying to not miss another technological revolution, governments are getting serious about reenergising legacy players such as Eutelsat Communications, which is in talks to raise 1.5 billion euros (S$2.2 billion) that would double the French state's stake to 30 per cent. The continent is also eyeing its first 'hop' test of a reusable booster project called Themis, which I glimpsed while on a recent tour of Airbus and Safran's Arianespace manufacturing facility near Paris. But one gloomy possibility is that a prolonged Maga-Musk war makes space a chillier place for everyone. Nasa is already facing hefty budget cuts; snapbacks and U-turns driven by personal rivalries won't inspire confidence. (Let's not forget Amazon once blamed Trump's personal dislike of Bezos for the loss of a US$10 billion Pentagon contract.) And Europeans have a huge gap to close: A report by think tank Institut Montaigne notes that its military space spending is one-fifteenth the US', while Bloomberg Intelligence's John Davies estimates Eutelsat's OneWeb network requires an extra four billion euros or more of capital spending by 2030. More mergers and more state meddling are likely in a de-Musking world – though hopefully with some lessons learnt ahead of time. BLOOMBERG
